

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 8, 2025

**Consolidated Financial Summary
for the Fiscal Year Ended March 31, 2025
(Under Japanese GAAP)**

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/english/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Koichi Tamura, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date of ordinary general meeting of shareholders: June 27, 2025

Scheduled date to commence dividend payments: June 30, 2025

Scheduled date to submit the Securities Report: June 26, 2025

Preparation of supplementary documents to the financial results: Yes

Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2024 through March 31, 2025)

(1) Consolidated Financial Results (Percentage figures indicate changes from the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2025	87,311	15.3	12,197	26.8	12,840	50.8	9,936	28.5
March 31, 2024	75,725	10.7	9,621	6.7	8,513	12.3	7,731	24.8

Note: Comprehensive income: For the year ended March 31, 2025: 11,952 million yen [(25.7)%]

For the year ended March 31, 2024: 16,089 million yen [25.1%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ordinary profit to total assets	Operating profit to net sales
Year ended	Yen	Yen	%	%	%
March 31, 2025	225.42	—	11.7	8.3	14.0
March 31, 2024	175.39	—	10.7	6.0	12.7

Reference: Share of profit (loss) of entities accounted for using equity method: For the year ended March 31, 2025: (276) million yen

For the year ended March 31, 2024: (76) million yen

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2025	159,171	89,797	56.3	2,031.33
March 31, 2024	150,533	79,828	52.9	1,806.33

Reference: Equity: As of March 31, 2025: 89,539 million yen As of March 31, 2024: 79,622 million yen

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of term
Year ended	Million yen	Million yen	Million yen	Million yen
March 31, 2025	12,922	(1,050)	(7,756)	23,467
March 31, 2024	12,183	(3,952)	(8,124)	18,604

2. Dividends

	Annual dividends					Total dividends paid (Total)	Payout ratio (Consolidated)	Dividend rate for net assets (Consolidated)
	First quarter	Second quarter	Third quarter	Year-end	Total			
Year ended March 31, 2024	Yen —	Yen 22.00	Yen —	Yen 22.00	Yen 44.00	Million yen 1,939	% 25.1	% 2.7
March 31, 2025	—	23.00	—	24.00	47.00	2,071	20.8	2.4
Year ending March 31, 2026 (Forecast)	—	24.00	—	24.00	48.00		22.3	

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026 (April 1, 2025 through March 31, 2026)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First six months	43,000	1.4	5,000	(22.6)	5,000	(37.1)	4,000	(34.0)	90.75
Full year	90,000	3.1	12,000	(1.6)	12,000	(6.5)	9,500	(4.4)	215.52

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

(3) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of March 31, 2025: 53,119,190 shares As of March 31, 2024: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of March 31, 2025: 9,039,667 shares As of March 31, 2024: 9,039,354 shares

3) Average number of shares during the term:

For the year ended March 31, 2025: 44,079,600 shares

For the year ended March 31, 2024: 44,080,055 shares

Reference: Summary of Non-consolidated Financial Results

Non-consolidated Financial Highlights (April 1, 2024 through March 31, 2025)

(1) Non-consolidated Financial Results

(Percentage figures indicate changes from the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2025	34,710	2.0	1,269	7.9	3,422	27.4	2,859	74.7
March 31, 2024	34,017	3.2	1,176	(34.4)	2,686	(1.9)	1,636	(24.2)

	Basic earnings per share	Diluted earnings per share
Year ended	Yen	Yen
March 31, 2025	64.86	—
March 31, 2024	37.12	—

(2) Non-consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2025	90,023	41,016	45.6	930.52
March 31, 2024	92,940	40,035	43.1	908.24

Reference: Equity: As of March 31, 2025: 41,016 million yen As of March 31, 2024: 40,035 million yen

* Financial Summary Is Exempt From Audit Conducted by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.